Tissue Microarrays for Routine Diagnostic Assessment of HER2 Status in Breast Carcinoma
- 1 March 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Applied Immunohistochemistry & Molecular Morphology
- Vol. 16 (2), 179-184
- https://doi.org/10.1097/pai.0b013e31806875e1
Abstract
The use of tissue microarray (TMA) technology may substantially reduce the costs of routine testing of breast carcinomas for human epidermal growth factor receptor 2 (HER2) status. After a preliminary pilot study comparing the TMA results with those obtained on whole section, which showed an excellent agreement (with kappa values >0.90) for both immunohistochemical and fluorescent in situ hybridization (FISH) method, we introduced the TMA technique in our routine work. A total of 1158 invasive breast carcinomas were submitted for the determination of HER2 status, which was assessed in 74 weekly runs. One hundred twenty-five of 1084 surgical specimens (11.5%) were judged as unsuitable for inclusion into TMAs. In 32 of 959 tumors included in TMAs (3.3%), the respective cores were uninformative, and HER2 status was determined on whole sections. Thus, HER2 status was finally determined on TMA in 927 cases (81.1%). A typical weekly run comprised 1 TMA (consisting, on average, of 13 tumors), 2 whole sections of surgical specimens and 1 whole section of core needle biopsy, and the number of processed slides for each method decreased from 16 to 4 per week. In all, 14.7% of tumors were HER2 positive by FISH. In both TMAs and whole sections, immunohistochemical results were in good agreement with FISH for cases scored as 0/1+ (98% and 97%) and for those scored as 3+ (96% and 87%), whereas concordance was poor in cases scored as 2+ (30% and 13%, respectively).Keywords
This publication has 27 references indexed in Scilit:
- Preoperative Profiling of Symptomatic Breast Cancer by Diagnostic Core BiopsyAnnals of Surgical Oncology, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Correlation of HER-2 Status With Estrogen and Progesterone Receptors and Histologic Features in 3,655 Invasive Breast CarcinomasAmerican Journal of Clinical Pathology, 2005
- HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ HybridizationAmerican Journal of Clinical Pathology, 2004
- Best Practice No 176: Updated recommendations for HER2 testing in the UKJournal of Clinical Pathology, 2004
- Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancerWiener klinische Wochenschrift, 2004
- Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centresThe Journal of Pathology, 2003
- Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast CancerLaboratory Investigation, 2003
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998